Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in renal pelvic carcinoma (UTUC), sponsored by The Second Hospital of Tianjin Medical University. Started Nov 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
renal pelvic carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07233252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233252.